Newborn screening for Pompe disease in Italy: Long-term results and future challenges

[1]  Yan Yan,et al.  Establishment of Cutoff Values for Newborn Screening of Six Lysosomal Storage Disorders by Tandem Mass Spectrometry , 2022, Frontiers in Pediatrics.

[2]  A. Burlina,et al.  Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel , 2022, Italian Journal of Pediatrics.

[3]  Y. Chien,et al.  Outcome of later-onset Pompe disease identified through newborn screening. , 2022, The Journal of pediatrics.

[4]  P. Kishnani,et al.  Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening. , 2022, Molecular genetics and metabolism.

[5]  B. Byrne,et al.  Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial , 2021, The Lancet Neurology.

[6]  A. Cano,et al.  Importance of Timely Treatment Initiation in Infantile-Onset Pompe Disease, a Single-Centre Experience , 2021, Children.

[7]  D. Rizopoulos,et al.  Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. , 2021, The Lancet. Child & adolescent health.

[8]  W. Wilcox,et al.  Health care practitioners' experience-based opinions on providing care after a positive newborn screen for Pompe disease. , 2021, Molecular genetics and metabolism.

[9]  W. Pijnappel,et al.  Broad variation in phenotypes for common GAA genotypes in Pompe disease , 2021, Human mutation.

[10]  F. Endo,et al.  Current status of newborn screening for Pompe disease in Japan , 2021, Orphanet Journal of Rare Diseases.

[11]  B. Byrne,et al.  Phenotypic implications of pathogenic variant types in Pompe disease , 2021, Journal of Human Genetics.

[12]  E. Lisi,et al.  Opinions of adults affected with later‐onset lysosomal storage diseases regarding newborn screening: A qualitative study , 2021, Journal of genetic counseling.

[13]  W. Craigen,et al.  Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via Newborn Screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction , 2021, Genetics in Medicine.

[14]  Damara N. Ortiz,et al.  Newborn Screening for Pompe Disease: Pennsylvania Experience , 2020, International journal of neonatal screening.

[15]  W. Pijnappel,et al.  Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience , 2020, European Journal of Human Genetics.

[16]  J. Orsini,et al.  The Impact of Post-Analytical Tools on New York Screening for Krabbe Disease and Pompe Disease , 2020, International journal of neonatal screening.

[17]  W. Pijnappel,et al.  Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients , 2020, Journal of inherited metabolic disease.

[18]  Jun Kido,et al.  Newborn Screening for Pompe Disease , 2020, International journal of neonatal screening.

[19]  J. Washburn,et al.  Lessons Learned from Pompe Disease Newborn Screening and Follow-up , 2020, International journal of neonatal screening.

[20]  S. Sciortino,et al.  The First Year Experience of Newborn Screening for Pompe Disease in California , 2020, International journal of neonatal screening.

[21]  M. Gelb,et al.  Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns , 2020, Orphanet Journal of Rare Diseases.

[22]  J. Charrow,et al.  Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants , 2020, International journal of neonatal screening.

[23]  W. Wilcox,et al.  Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction , 2020, International journal of neonatal screening.

[24]  L. Hoefsloot,et al.  Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis , 2020, Molecular therapy. Methods & clinical development.

[25]  M. ElMallah,et al.  Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature , 2020, Genetics in Medicine.

[26]  W. Pijnappel,et al.  Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity , 2019, Human mutation.

[27]  L. Salviati,et al.  Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy , 2019, International journal of neonatal screening.

[28]  F. Endo,et al.  Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients , 2019, Journal of Human Genetics.

[29]  B. Bembi,et al.  A genetic modifier of symptom onset in Pompe disease , 2019, EBioMedicine.

[30]  W. Pijnappel,et al.  Effects of immunomodulation in classic infantile Pompe patients with high antibody titers , 2019, Orphanet Journal of Rare Diseases.

[31]  Y. Chien,et al.  Newborn screening: Taiwanese experience. , 2019, Annals of translational medicine.

[32]  T. Mongini,et al.  Early higher dosage of alglucosidase alpha in classic Pompe disease , 2018, Journal of pediatric endocrinology & metabolism : JPEM.

[33]  Y. Chien,et al.  Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease , 2018, International journal of neonatal screening.

[34]  Sean M. Bailey,et al.  The New York Pilot Newborn Screening Program for Lysosomal Storage Diseases: Report of the First 65,000 Infants , 2018, Genetics in Medicine.

[35]  P. Rinaldo,et al.  Precision newborn screening for lysosomal disorders , 2018, Genetics in Medicine.

[36]  P. Rinaldo,et al.  Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease , 2018, Genetics in Medicine.

[37]  Jennifer S. Li,et al.  Severe Cardiac Involvement Is Rare in Patients with Late‐Onset Pompe Disease and the Common c.‐32‐13T>G Variant: Implications for Newborn Screening , 2018, The Journal of pediatrics.

[38]  R. Giugliani,et al.  Neonatal screening for four lysosomal storage diseases with a digital microfluidics platform: Initial results in Brazil , 2018, Genetics and molecular biology.

[39]  F. Aarsen,et al.  Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain , 2018, Developmental medicine and child neurology.

[40]  N. C. van de Merbel,et al.  High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy , 2018, The Journal of pediatrics.

[41]  E. Lisi,et al.  Newborn screening for Pompe disease: impact on families , 2018, Journal of Inherited Metabolic Disease.

[42]  R. Desnick,et al.  Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy , 2018, Journal of Inherited Metabolic Disease.

[43]  J. Charrow,et al.  Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15‐Month Experience , 2017, The Journal of pediatrics.

[44]  P. Kishnani,et al.  Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant. , 2017, Molecular genetics and metabolism.

[45]  E. C. Neto,et al.  Investigation of newborns with abnormal results in a newborn screening program for four lysosomal storage diseases in Brazil , 2017, Molecular genetics and metabolism reports.

[46]  W. Hwu,et al.  Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum , 2017, Pediatrics.

[47]  J. Reyna-Figueroa,et al.  Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: Three-year findings from a screening program in a closed Mexican health system. , 2017, Molecular genetics and metabolism.

[48]  M. Gelb,et al.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease. , 2017, Clinical chemistry.

[49]  M. Araúzo-Bravo,et al.  GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells , 2017, Molecular therapy. Nucleic acids.

[50]  I. Nishino,et al.  Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state , 2016, Molecular genetics and metabolism reports.

[51]  Dawn A. Laney,et al.  Patients' perspectives on newborn screening for later-onset lysosomal storage diseases. , 2016, Molecular genetics and metabolism.

[52]  M. Gelb,et al.  Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry , 2016, Molecular genetics and metabolism.

[53]  J. Rogers,et al.  Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with Late-Onset Pompe Disease: A Case Report. , 2016, JIMD reports.

[54]  S. McCandless,et al.  Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers , 2016, Journal of Genetic Counseling.

[55]  F. Aarsen,et al.  Cognitive decline in classic infantile Pompe disease: An underacknowledged challenge , 2016, Neurology.

[56]  A. Broomfield,et al.  Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy , 2016, Journal of Inherited Metabolic Disease.

[57]  W. Soong,et al.  Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes. , 2016, The Journal of pediatrics.

[58]  A. T. van der Ploeg,et al.  Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study , 2016, Journal of Inherited Metabolic Disease.

[59]  C. Rehder,et al.  Clinical laboratory experience of blood CRIM testing in infantile Pompe disease , 2015, Molecular genetics and metabolism reports.

[60]  P. Rinaldo,et al.  Newborn screening for lysosomal storage disorders. , 2015, Seminars in perinatology.

[61]  C. V. van El,et al.  Newborn screening for pompe disease? a qualitative study exploring professional views , 2014, BMC Pediatrics.

[62]  P. Laforêt,et al.  Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease , 2014, Neuromuscular Disorders.

[63]  F. Tsai,et al.  Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[64]  Patricia M Okamoto,et al.  A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease. , 2014, Molecular genetics and metabolism.

[65]  Chih-jou Lai,et al.  A large‐scale nationwide newborn screening program for pompe disease in Taiwan: Towards effective diagnosis and treatment , 2014, American journal of medical genetics. Part A.

[66]  M. Kruijshaar,et al.  Phenotypical variation within 22 families with Pompe disease , 2013, Orphanet Journal of Rare Diseases.

[67]  J. Charrow,et al.  Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT , 2013, PloS one.

[68]  T. Beccari,et al.  First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[69]  Y. Chien,et al.  Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. , 2012, Molecular genetics and metabolism.

[70]  H. Runz,et al.  A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations , 2012, Orphanet Journal of Rare Diseases.

[71]  F. Aarsen,et al.  Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy , 2012, Neurology.

[72]  P. Kostense,et al.  Public support for neonatal screening for Pompe disease, a broad-phenotype condition , 2012, Orphanet Journal of Rare Diseases.

[73]  G. Spiridigliozzi,et al.  Early cognitive development in children with infantile Pompe disease. , 2012, Molecular Genetics and Metabolism.

[74]  P. Kishnani,et al.  Infantile Pompe disease on ERT—Update on clinical presentation, musculoskeletal management, and exercise considerations , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[75]  C. Rehder,et al.  Assessing disease severity in Pompe disease: The roles of a urinary glucose tetrasaccharide biomarker and imaging techniques , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[76]  Thomas P. Mechtler,et al.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria , 2012, The Lancet.

[77]  J. Murillo,et al.  Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. , 2011, Molecular genetics and metabolism.

[78]  M. Watson,et al.  Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals , 2011, Genetics in Medicine.

[79]  Stefan Timmermans,et al.  Patients-in-Waiting , 2010, Journal of health and social behavior.

[80]  A. Pestronk,et al.  A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.

[81]  Y. Chien,et al.  Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. , 2010, Molecular genetics and metabolism.

[82]  Y. Chien,et al.  Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment , 2009, Pediatrics.

[83]  J. Clancy,et al.  Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.

[84]  Faye Kokotos.  The Vulnerable Child Syndrome , 2009, Pediatrics in review.

[85]  B. Byrne,et al.  Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease , 2009, Genetics in Medicine.

[86]  O. Bodamer,et al.  Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. , 2008, Clinical chemistry.

[87]  R. Wevers,et al.  p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? , 2008, European Journal of Human Genetics.

[88]  Y. Chien,et al.  Early Detection of Pompe Disease by Newborn Screening Is Feasible: Results From the Taiwan Screening Program , 2008, Pediatrics.

[89]  Yuan-Tsong Chen,et al.  Sibling phenotype concordance in classical infantile Pompe disease , 2007, American journal of medical genetics. Part A.

[90]  S. Tsujino,et al.  Structural and biochemical studies on Pompe disease and a “pseudodeficiency of acid α-glucosidase” , 2007, Journal of Human Genetics.

[91]  B. Thurberg,et al.  Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease , 2006, Laboratory Investigation.

[92]  Y. Chien,et al.  Brain Development in Infantile-Onset Pompe Disease Treated by Enzyme Replacement Therapy , 2006, Pediatric Research.

[93]  R. Moreland,et al.  Lysosomal Acid α-Glucosidase Consists of Four Different Peptides Processed from a Single Chain Precursor* , 2005, Journal of Biological Chemistry.

[94]  C. I. Zeeuw,et al.  Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse , 2004, Neurobiology of Disease.

[95]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[96]  G. Uziel,et al.  Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. , 2002, The Journal of pediatrics.

[97]  C. Boerkoel,et al.  Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. , 1995, American journal of human genetics.

[98]  Y. Chien,et al.  Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening. , 2015, JIMD reports.

[99]  Y. Chien,et al.  Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype. , 2014, JIMD reports.

[100]  A. Rolfs,et al.  Newborn screening for lysosomal storage disorders in hungary. , 2012, JIMD reports.

[101]  F. Glocker,et al.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial , 2009, Journal of Neurology.